Study guide
11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
Board Certified Specialist in Renal Nutrition CSR
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Kidney Disease Foundations
1.1 CDR CSR Exam Structure, Eligibility, Logistics & the 2023 Content Outline 1.2 Renal Anatomy, Physiology & Glomerular Hemodynamics 1.3 CKD Etiology, KDIGO Staging & Progression Risk
2 Chapter 2: Domain 1 — Anthropometric & Body Composition Assessment
2.1 Dry Weight Determination, Fluid Assessment & Interdialytic Weight Gain 2.2 Anthropometric Measurement Standards (Knee Height, Skinfolds, Frame Size) 2.3 Body Composition Analysis: BIA, BIS, DXA & Handgrip Dynamometry
3 Chapter 3: Domain 1 — Nutrition-Focused Physical Findings & PEW Assessment Tools
3.1 Protein-Energy Wasting (PEW) Diagnostic Criteria & Pathophysiology 3.2 Subjective Global Assessment (7-Point SGA) in Dialysis 3.3 Malnutrition Inflammation Score (MIS) & Scoring Protocols 3.4 Nutrition-Focused Physical Exam (NFPE) for Muscle & Fat Loss
4 Chapter 4: Domain 1 — Diet, Medical, Medication & Psychosocial History
4.1 Dietary Intake Assessment & Food Frequency Methods in CKD 4.2 Medical & Medication History: Drug–Nutrient Interactions and Supplements 4.3 Psychosocial, Social & Functional History in Renal Nutrition Assessment
5 Chapter 5: Domain 1 — Medical Tests & Procedures by Treatment Modality
5.1 Hemodialysis Clinical Assessment & Vascular Access Considerations 5.2 Peritoneal Dialysis & Peritoneal Glucose Absorption Assessment 5.3 AKI, CRRT & Pediatric Renal Disease Assessment
6 Chapter 6: Domain 1 — Nutrition Diagnosis: Terminology, Etiology & Reasoning
6.1 Standardized Nutrition Diagnostic Terminology (NCP) in Nephrology 6.2 Etiology & Root-Cause Analysis for Renal Nutrition Problems 6.3 Diagnostic Reasoning for Fluid, Mineral & Protein Imbalances
7 Chapter 7: Domain 1 — Nutrition Diagnosis in Complex Patients
7.1 Formulating Valid PES Statements in Complex Dialysis Patients 7.2 Differentiating PEW, Sarcopenia & Cachexia in CKD 7.3 Diagnostic Prioritization across Cardiorenal & Diabetic Nephropathy
8 Chapter 8: Domain 2 — Food & Nutrient Delivery: Protein & Energy
8.1 KDOQI 2020 Protein Targets: Non-Dialysis CKD (LPD vs. VLPD) 8.2 Protein Prescriptions for Hemodialysis and Peritoneal Dialysis 8.3 Energy Requirements, Carbohydrates & Plant-Dominant Diets (PLADO)
9 Chapter 9: Domain 2 — Electrolytes, Fluid, Acid–Base & Micronutrients
9.1 Potassium Management: Dietary Restriction, Leaching & K-Binders 9.2 Sodium & Fluid Prescriptions across Dialysis Modalities 9.3 Acid-Base Homeostasis & Bicarbonate Replacement Therapy 9.4 Micronutrient, Trace Mineral & Vitamin Supplementation in ESRD
10 Chapter 10: Domain 2 — Medications & Specialized Nutrition Support
10.1 CKD-MBD Pharmacology: Phosphorus Binders, Vitamin D & Calcimimetics 10.2 Anemia Management: Iron Homeostasis, IV Iron Protocols & ESAs 10.3 Enteral, IDPN & Intraperitoneal Amino Acid Nutrition Support
11 Chapter 11: Domain 2 — Treatments Across the Continuum: Transplant & Comorbidities
11.1 Kidney Transplant I: Candidacy, Living Donors & the Early Post-Transplant Period 11.2 Kidney Transplant II: Long-Term Care, Immunosuppressant Side Effects & Graft Protection 11.3 Diabetes Management Across CKD Stages: Glycemic Targets, Medications & MNT 11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
12 Chapter 12: Domain 2 — Monitoring & Evaluation: Labs, Fluid & Nutrition Trends
12.1 Renal Laboratory Surveillance: Frequency, Target Ranges & Trending 12.2 Monitoring Fluid Balance, Blood Pressure & Cardiovascular Risk 12.3 Longitudinal Assessment of Nutritional Status & Weight Trajectories
13 Chapter 13: Domain 2 — Monitoring Dialysis Adequacy & Kinetics
13.1 Hemodialysis Adequacy: Urea Kinetic Modeling, spKt/V & URR 13.2 Peritoneal Dialysis Adequacy & Peritoneal Equilibration Test (PET) 13.3 Normalized Protein Catabolic Rate (nPCR / nPNA) Interpretation 13.4 Troubleshooting Inadequate Dialysis vs. Dietary Non-Adherence
14 Chapter 14: Domain 2 — Care Coordination, Communication & Education
14.1 Interdisciplinary Team Care, Patient Education & Counseling Ethics 14.2 Individualized & Group Education: Medicare MNT and KDE Benefits, Caregivers & Curricula 14.3 Interfacility Coordination of Care: Hospital Handoffs, Transfers, Transplant Centers & Modality Changes 14.4 Psychosocial Support & Resources: Food Assistance, Financial Programs, Rehabilitation & Peer Support
15 Chapter 15: Domain 3 — Regulations & Quality Management
15.1 CMS Conditions for Coverage: IDT, Dietitian Qualifications, Assessment & Plan-of-Care Timelines 15.2 QAPI Programs, PDSA Cycles & the ESRD Quality Incentive Program 15.3 Medicare ESRD Payment, ESRD Networks, EQRS & the Survey Measures Assessment Tool
16 Chapter 16: Domain 3 — Evidence-Based Practice: Guidelines, Research & Protocols
16.1 The KDOQI 2020 Nutrition in CKD Guideline (NKF–Academy EAL): Grades & Key Statements 16.2 KDIGO & Companion Guidelines: CKD 2024, CKD-MBD, Anemia 2026, Diabetes, BP, Lipids & AKI 16.3 Appraising Current Research: Study Designs, Bias, Statistics & Landmark Renal Trials 16.4 Clinical Protocols & Algorithms: Dietitian-Managed MBD, Anemia, Potassium & Nutrition-Support Pathways
11.4 GI & Cardiovascular Comorbidities: Gastroparesis, Constipation, Liver Disease, Lipids & Blood Pressure
Key Takeaways Explain This Topic AI
Constipation in CKD reduces colonic potassium excretion; fiber within potassium limits and a bowel regimen that avoids magnesium and sodium phosphate products are preferred.
Sodium phosphate enemas and magnesium-based laxatives are avoided in advanced CKD because they can cause severe hyperphosphatemia or hypermagnesemia.
KDIGO 2013 recommends a statin or statin/ezetimibe for adults 50 or older with CKD not on dialysis, and advises not starting statins in people on dialysis.
KDIGO 2021 suggests a systolic blood-pressure target below 120 mmHg, when tolerated, for adults with CKD not on dialysis, using standardized office measurement.
KDOQI 2020 suggests 1.3–4 g/day of long-chain omega-3 fatty acids can lower triglycerides in hemodialysis, but suggests against routine use to reduce mortality or cardiovascular events.
Last updated: September 2026
Why these comorbidities are tested together
The CSR outline lists "comorbidities (e.g., diabetes, gastrointestinal, cardiovascular disease)" under Domain 2 treatments, and one task asks you to recommend management plans for GI and cardiovascular disease. Both are common in kidney disease, both change nutrient needs, and both interact with potassium, phosphorus and fluid management.
- Gastrointestinal comorbidities
- Gastroparesis
Diabetic autonomic neuropathy and uremia slow gastric emptying, causing early satiety, bloating, nausea, vomiting and erratic glucose.
Diet: small, frequent meals; lower fat and lower insoluble fiber; smooth or pureed textures; liquid calories when solids fail. Stay upright after meals.
Medications: metoclopramide dosing must be reduced in CKD because it accumulates and carries a risk of tardive dyskinesia. The prescriber decides.
Glucose: match insulin timing to actual absorption; mealtime insulin given after the meal may reduce hypoglycemia.
Severe cases: consider jejunal feeding or other support when oral intake stays inadequate.
Constipation
Constipation is very common with fluid limits, low fiber intake, inactivity, calcium binders, oral iron and opioids.
Why it matters: in advanced CKD, the colon excretes more of the daily potassium load. Constipation blocks that route and can raise serum potassium. In PD, a loaded colon can also displace the catheter and impair drainage.
Diet: add fiber from lower-potassium sources (for example, berries, apples, cabbage, green beans, and oats in portions) and moving fluid allowances toward water.
Laxatives: polyethylene glycol, lactulose, senna and stool softeners are generally acceptable. Avoid magnesium-based laxatives (magnesium citrate, milk of magnesia) and sodium phosphate enemas or oral solutions , which can cause dangerous hypermagnesemia or hyperphosphatemia and acute phosphate nephropathy.
Diarrhea and malabsorption
Diarrhea (from mycophenolate, infection, diabetic enteropathy or antibiotics) causes losses of potassium, magnesium, bicarbonate and fluid. Monitor electrolytes and adjust restrictions to the labs; a dialysis patient with ongoing diarrhea may need less potassium restriction, not more.
GI bleeding and anemia
Angiodysplasia, ulcers and uremic platelet dysfunction make GI bleeding more common in CKD. Blood in the gut is a protein load that raises BUN, and blood loss drives iron deficiency. Iron-based binders (ferric citrate, sucroferric oxyhydroxide) and oral iron turn stools dark, so teach patients to report black, tarry or sticky stools or other signs of bleeding rather than assuming the binder explains them.
Liver disease with CKD
Cirrhosis: protein should not be restricted to prevent encephalopathy; hepatology guidance supports normal-to-high protein spread through the day, with a late-evening snack. Sodium restriction manages ascites. Hepatorenal physiology makes fluid balance fragile.
Hepatitis C: managed under KDIGO's hepatitis C guideline; curative antiviral therapy is used in CKD, dialysis and before transplant.
Fatty liver disease: follows weight and metabolic management.
Other GI issues
Uremic gastritis, GERD and dysgeusia reduce intake. PD adds early satiety from abdominal fill volume and hernia risk. Pancreatitis can follow severe hypertriglyceridemia.
Cardiovascular comorbidities
Cardiovascular disease is the leading cause of death in dialysis patients, and CKD is itself a major cardiovascular risk factor. Much dialysis death is sudden cardiac death and heart failure rather than classic atherosclerotic events, so volume control, potassium safety and mineral balance matter alongside lipids.
Lipids (KDIGO 2013 Lipid Management in CKD)
- Group KDIGO statement
- Age ≥50, eGFR <60, not on dialysis or transplanted Statin or statin/ezetimibe recommended (1A)
- Age ≥50 with eGFR ≥60 Statin recommended (1B)
Age 18–49, not on dialysis Statin suggested if coronary disease, diabetes, prior ischemic stroke or high 10-year risk is present
- On dialysis, not already on a statin Do not start statin or statin/ezetimibe (2A)
- On dialysis and already taking one Continue it (2C)
- Kidney transplant recipients Statin suggested (2B)
Diet still matters for lipids: replace saturated and trans fat with unsaturated fats, add soluble fiber and plant proteins as potassium and phosphorus allow, and limit sugar and alcohol when triglycerides are high. KDOQI 2020 statements on fats:
a Mediterranean diet may improve lipid profiles in CKD 1–5 not on dialysis and after transplant (3.3.1, 2C);
in maintenance HD, 1.3–4 g/day of long-chain omega-3 fatty acids may lower triglycerides and LDL (2C) and raise HDL (2D);
in CKD 3–5, about 2 g/day lowers triglycerides (2C);
but do not routinely prescribe omega-3s in HD to reduce mortality (2C) or cardiovascular events (2B) , and do not prescribe fish oil to improve AV graft or fistula patency.
Blood pressure
Non-dialysis CKD: KDIGO's 2021 blood-pressure guideline suggests a systolic target below 120 mmHg when tolerated , using standardized office measurement.
Dialysis: targets rely on dry-weight management. The CMS Measures Assessment Tool (citing KDOQI 2005) lists pre-dialysis BP below 140/90 and post-dialysis below 130/80 mmHg for adults.
Nutrition levers: sodium restriction (KDOQI <2.3 g/day; KDIGO 2024 <2 g/day), weight control, a DASH-style pattern where potassium allows, limited alcohol and physical activity.
Heart failure
Heart failure with kidney disease (cardiorenal syndrome) requires tight sodium control, a fluid plan coordinated with diuretics or ultrafiltration, attention to potassium when RAAS blockers, mineralocorticoid antagonists or SGLT2 inhibitors are used, and protection against cardiac cachexia. Section 7.3 covers how to prioritize these problems.
Balancing heart-healthy eating with renal limits
"Heart-healthy" handouts often push high-potassium foods, whole grains and dairy in amounts that clash with dialysis limits. Individualize: choose lower-potassium produce and leach where needed, use portion control for whole grains and nuts, prefer fresh unprocessed proteins, and never cut protein below the patient's CKD or dialysis target to lower cholesterol.